{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T04:17:11Z","timestamp":1788754631602,"version":"build-2803163510"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:sec>\n            <jats:title>Objective:<\/jats:title>\n            <jats:p>The therapeutic effects of antimotion sickness medications involve suppression of several components along the vestibular system. Scopolamine-based medications have proved to be the most effective anti-seasickness agents. However, there is high variability in individual responses. The vestibular nuclei, in which the vestibular time constant is modulated, contain acetylcholine receptors which are affected by scopolamine. The hypothesis of the study was that successful seasickness prevention by scopolamine requires vestibular suppression to be reflected by the shortening of the vestibular time constant.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Design:<\/jats:title>\n            <jats:p>Subjects were 30 naval crew members suffering from severe seasickness and were treated with oral scopolamine. The study participants were defined as responsive or non-responsive to the anti-seasickness medication according to the clinical outcome: successful response to scopolamine was defined as a reduction of seasickness severity from the highest score of 7 according to the Wiker scale to 4 or less. Scopolamine and placebo were assigned to each subject in a crossover, double-blind design. The horizontal semicircular canal time constant was evaluated by a computerized rotatory chair before, 1 and 2 hours after drug or placebo administration.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The vestibular time constant was significantly shortened from 16.01\u2009\u00b1\u20093.43 seconds to 12.55\u2009\u00b1\u20092.40 seconds (<jats:italic toggle=\"yes\">p<\/jats:italic> &lt; 0.001) in the scopolamine-responsive group but not in the nonresponsive group. In contrast, vestibular time constant values were 13.73\u2009\u00b1\u20094.08 and 12.89\u2009\u00b1\u20094.48 for baseline and 2 hours measurements, respectively. This change was not statistically significant.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Reduction in the vestibular time constant after scopolamine administration can be used to predict whether motion sickness alleviation will occur. This will enable the administration of appropriate pharmaceutical treatment without the need for prior exposure to sea conditions.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/aud.0000000000001385","type":"journal-article","created":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T04:02:03Z","timestamp":1684900923000},"page":"1404-1409","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["The Vestibular Time Constant and Clinical Response to Antimotion Sickness Medication"],"prefix":"10.1097","volume":"44","author":[{"given":"Daniel","family":"Lagami","sequence":"first","affiliation":[{"name":"Motion Sickness and Human Performance Laboratory, Israel Naval Medical Institute, IDF Medical Corps, Haifa, Israel"},{"name":"Bruce Rappaport Faculty of Medicine, Technion\u2014Israel Institute of Technology, Haifa, Israel"},{"name":"Department of Brain Sciences, Weizmann Institute of Science, Rehovot, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avi","family":"Shupak","sequence":"additional","affiliation":[{"name":"Bruce Rappaport Faculty of Medicine, Technion\u2014Israel Institute of Technology, Haifa, Israel"},{"name":"Unit of Otoneurology, Lin Medical Center, Haifa, Israel"},{"name":"Department of Communication Science and Disorders, Faculty of Social Welfare and Health Sciences, University of Haifa, Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Jamison","sequence":"additional","affiliation":[{"name":"Motion Sickness and Human Performance Laboratory, Israel Naval Medical Institute, IDF Medical Corps, Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dror","family":"Tal","sequence":"additional","affiliation":[{"name":"Motion Sickness and Human Performance Laboratory, Israel Naval Medical Institute, IDF Medical Corps, Haifa, Israel"},{"name":"Department of Military Medicine, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,5,24]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1592\/phco.29.9.1082","article-title":"Safety of double-dose transdermal scopolamine.","volume":"29","author":"Bar","year":"2009","journal-title":"Pharmacotherapy"},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s004210100494","article-title":"Effects of cosmonaut vestibular training on vestibular function prior to spaceflight.","volume":"85","author":"Cl\u00e9ment","year":"2001","journal-title":"Eur J Appl Physiol"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1749-6632.1981.tb30888.x","article-title":"Velocity storage, nystagmus, and visual-vestibular interactions in humans.","volume":"374","author":"Cohen","year":"1981","journal-title":"Ann N Y Acad Sci"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0079-6123(08)00677-8","article-title":"Baclofen, motion sickness susceptibility and the neural basis for velocity storage.","volume":"171","author":"Cohen","year":"2008","journal-title":"Prog Brain Res"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00221-011-2548-8","article-title":"Prolonged reduction of motion sickness sensitivity by visual-vestibular interaction.","volume":"210","author":"Dai","year":"2011","journal-title":"Exp Brain Res"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/WNF.0b013e31823dc125","article-title":"A comparison of cinnarizine and transdermal scopolamine for the prevention of seasickness in naval crew: a double-blind, randomized, crossover study.","volume":"35","author":"Gil","year":"2012","journal-title":"Clin Neuropharmacol"},{"key":"R8-20250526","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/B978-0-444-63437-5.00027-3","article-title":"Motion sickness.","volume":"137","author":"Golding","year":"2016","journal-title":"Handb Clin Neurol"},{"key":"R9-20250526","first-page":"521","article-title":"Scopolamine blood levels following buccal versus ingested tablets.","volume":"62","author":"Golding","year":"1991","journal-title":"Aviat Space Environ Med"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1097\/00129492-200307000-00017","article-title":"Vestibular testing abnormalities in individuals with motion sickness.","volume":"24","author":"Hoffer","year":"2003","journal-title":"Otol Neurotol"},{"key":"R13-20250526","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1152\/ajplegacy.1970.219.5.1248","article-title":"Effects of belladonna alkaloids on vestibular nucleus of the cat.","volume":"219","author":"Jaju","year":"1970","journal-title":"Am J Physiol"},{"key":"R14-20250526","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0022-3565(24)29671-3","article-title":"Scopolamine bioavailability in combined oral and transdermal delivery.","volume":"296","author":"Nachum","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"R15-20250526","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/BF00174373","article-title":"The effects of transdermal scopolamine and four dose levels of oral scopolamine (0.15, 0.3, 0.6, and 1.2\u2009mg) upon psychological performance.","volume":"89","author":"Parrott","year":"1986","journal-title":"Psychopharmacology (Berl)"},{"key":"R16-20250526","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1023\/A:1015916423156","article-title":"Pharmacokinetics and oral bioavailability of scopolamine in normal subjects.","volume":"6","author":"Putcha","year":"1989","journal-title":"Pharm Res"},{"key":"R17-20250526","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3109\/00016488509182266","article-title":"Transdermally administered scopolamine vs. dimenhydrinate. II. Effect on different types of nystagmus.","volume":"99","author":"Pyykk\u00f6","year":"1985","journal-title":"Acta Otolaryngol"},{"key":"R19-20250526","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1097\/01.ftd.0000168293.48226.57","article-title":"Pharmacokinetics and pharmacodynamics in clinical use of scopolamine.","volume":"27","author":"Renner","year":"2005","journal-title":"Ther Drug Monit"},{"key":"R20-20250526","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000350185","article-title":"Neuronal mechanisms and the treatment of motion sickness.","volume":"91","author":"Schm\u00e4l","year":"2013","journal-title":"Pharmacology"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1001\/archotol.1986.03780010090017","article-title":"Alleviation of induced vertigo. Therapy with transdermal scopolamine and oral meclizine.","volume":"112","author":"Schmitt","year":"1986","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"R22-20250526","first-page":"541","article-title":"Effect of transdermally administered scopolamine on the vestibular system in humans.","volume":"504","author":"Shojaku","year":"1993","journal-title":"Acta Otolaryngol Suppl"},{"key":"R23-20250526","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3109\/00016489309126205","article-title":"Neuropharmacology of motion sickness and emesis. A review.","volume":"501","author":"Takeda","year":"1993","journal-title":"Acta Otolaryngol Suppl"},{"key":"R24-20250526","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/BF00239041","article-title":"Neuronal activity in the vestibular nuclei of the alert monkey during vestibular and optokinetic stimulation.","volume":"27","author":"Waespe","year":"1977","journal-title":"Exp Brain Res"},{"key":"R25-20250526","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1523\/JNEUROSCI.01-02-00176.1981","article-title":"Autoradiographic localization of muscarinic cholinergic receptors in rat brainstem.","volume":"1","author":"Wamsley","year":"1981","journal-title":"J Neurosci"},{"key":"R28-20250526","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2165\/00003495-197917060-00003","article-title":"Antimotion sickness and antiemetic drugs.","volume":"17","author":"Wood","year":"1979","journal-title":"Drugs"},{"key":"R29-20250526","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3389\/fneur.2017.00386","article-title":"Coding of velocity storage in the vestibular nuclei.","volume":"8","author":"Yakushin","year":"2017","journal-title":"Front Neurol"},{"key":"R30-20250526","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0361-9230(98)00092-6","article-title":"Physiological basis and pharmacology of motion sickness: an update.","volume":"47","author":"Yates","year":"1998","journal-title":"Brain Res Bull"}],"container-title":["Ear &amp; Hearing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/AUD.0000000000001385","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T21:03:38Z","timestamp":1748293418000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/AUD.0000000000001385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,24]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/aud.0000000000001385","relation":{},"ISSN":["1538-4667"],"issn-type":[{"value":"1538-4667","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,24]]}}}